2778. Retrospective evaluation of effectiveness of Flomoxef for infections due to extended-spectrum β-lactamase-producing Enterobacterales

BACKGROUND: Flomoxef (FMOX), an oxacephem, is resistant to hydrolysis by extended-spectrum β-lactamase (ESBL), and is expected to serve as a carbapenem-sparing therapy for infections caused by ESBL-producing Enterobacterales (ESBLPE). FMOX has been approved and used in Japan for the treatment of ESB...

Descripción completa

Detalles Bibliográficos
Autores principales: Koizumi, Ryuji, Hayakawa, Kayoko, Hamada, Yukihiro, Mezaki, Kazuhisa, Ohmagari, Norio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677099/
http://dx.doi.org/10.1093/ofid/ofad500.2389

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677099/
http://dx.doi.org/10.1093/ofid/ofad500.2389

Ejemplares similares